Positive efficacy data boosts bid to broaden Taltz label

16 June 2017

With regulatory approval for a broader label pending in the USA, Eli Lilly (NYSE: LLY) has released more data on psoriatic arthritis candidate Taltz (ixekizumab) supporting the efficacy of the IL-17A inhibitor.

Data presented orally at EULAR, the Annual European Congress of Rheumatology, currently underway in Madrid, show that patients who had inadequate response or were intolerant to TNF inhibitors achieved significant improvement at 24 weeks.

Lilly has applied to extend the marketable application of Taltz in the USA, to include treatment of adult patients with active PsA. It is approved for this indication in Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK